Eric Alton is Professor of Gene Therapy and Respiratory Medicine, National Heart & Lung Institute, Imperial College London and Honorary Consultant Physician, Royal Brompton Hospital
Professor Alton was educated at Jesus College, Cambridge and Westminster Medical School and subsequently undertook six years of general medical training. Over the last fifteen years, he has been involved in developing gene therapy for cystic fibrosis and angiogenesis, including three clinical trials.
Professor Alton coordinates the UK CF Gene Therapy Consortium which brings together the three centres in the UK (Edinburgh and Oxford Universities and Imperial College), including approximately 80 clinicians and scientists focused on this problem.
et al., 2021, Assessment of F/HN Pseudotyped Lentiviral Vector Following Intravenous Delivery to Mice, CELL PRESS, Pages:138-139, ISSN:1525-0016
et al., 2021, Assessment of the Air-Liquid Interface Culture Model as a Tool to Validate Efficacy of a rSIV.F/HN-CFTR Vector, CELL PRESS, Pages:260-260, ISSN:1525-0016
et al., 2021, Biosafety Risk Assessment: Biodistribution and Environmental Shedding of Topically Administered Lentiviral Vector to the Murine Airway, CELL PRESS, Pages:259-260, ISSN:1525-0016
et al., 2021, Gene Therapy for Autoimmune Pulmonary Alveolar Proteinosis, CELL PRESS, Pages:256-257, ISSN:1525-0016
et al., 2021, Towards Enhancing Signal Peptides for Respiratory Gene Therapy with Secreted Proteins, CELL PRESS, Pages:139-139, ISSN:1525-0016